Evidence map›Paper›PMID 21203469›Full record

ArticlePloS one2010

Loss of caveolin-1 accelerates neurodegeneration and aging.

Brian P Head, Jason N Peart, Mathivadhani Panneerselvam, Takaakira Yokoyama, Matthew L Pearn, Ingrid R Niesman, Jacqueline A Bonds, Jan M Schilling, Atsushi Miyanohara, John Headrick and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

110 citing papers in PubMed, 1 synthesis or guideline pooled it, 188 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Is Caveolin-1 Required for Retinal Neuroprotection?Advances in experimental medicine and biology · 2025
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

50 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Brian P HeadDepartment of Anesthesiology, University of California San Diego, La Jolla, California, United States of America.
Jason N Peart
Mathivadhani Panneerselvam
Takaakira Yokoyama
Matthew L Pearn
Ingrid R Niesman
Jacqueline A Bonds
Jan M Schilling
Atsushi Miyanohara
John Headrick
Sameh S Ali
David M Roth
Piyush M Patel
Hemal H Patel
University of California, San Diego · USVA San Diego Healthcare System · USNational Heart Foundation of Australia · AU

Funding

Caveolae, mitochondria, and cardiac protection.R01HL091071 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PATEL, HEMAL H · 2008 to 2019
$3.8M
The role of caveolin-1 on anesthetic-mediated neurotoxicityK08GM124500 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PEARN, MATTHEW L · 2018 to 2022
$1.0M
Detection of Intracellular Oxygen SpeciesK25AG026379 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ALI, SAMEH S · 2007 to 2011
$687k
NHLBI NIH HHS R01 HL091071NIA NIH HHS K25 AG026379NIGMS NIH HHS K08 GM124500NIGMS NIH HHS L40 GM125142
6 · The paper itself

Abstract

backgroundThe aged brain exhibits a loss in gray matter and a decrease in spines and synaptic densities that may represent a sequela for neurodegenerative diseases such as Alzheimer's. Membrane/lipid rafts (MLR), discrete regions of the plasmalemma enriched in cholesterol, glycosphingolipids, and sphingomyelin, are essential for the development and stabilization of synapses. Caveolin-1 (Cav-1), a cholesterol binding protein organizes synaptic signaling components within MLR. It is unknown whether loss of synapses is dependent on an age-related loss of Cav-1 expression and whether this has implications for neurodegenerative diseases such as Alzheimer's disease. METHODOLOGY/PRINCIPAL

findingsWe analyzed brains from young (Yg, 3-6 months), middle age (Md, 12 months), aged (Ag, >18 months), and young Cav-1 KO mice and show that localization of PSD-95, NR2A, NR2B, TrkBR, AMPAR, and Cav-1 to MLR is decreased in aged hippocampi. Young Cav-1 KO mice showed signs of premature neuronal aging and degeneration. Hippocampi synaptosomes from Cav-1 KO mice showed reduced PSD-95, NR2A, NR2B, and Cav-1, an inability to be protected against cerebral ischemia-reperfusion injury compared to young WT mice, increased Aβ, P-Tau, and astrogliosis, decreased cerebrovascular volume compared to young WT mice. As with aged hippocampi, Cav-1 KO brains showed significantly reduced synapses. Neuron-targeted re-expression of Cav-1 in Cav-1 KO neurons in vitro decreased Aβ expression.

conclusionsTherefore, Cav-1 represents a novel control point for healthy neuronal aging and loss of Cav-1 represents a non-mutational model for Alzheimer's disease.

Indexed as

AgingAlzheimer DiseaseAnimalsBrainCaveolin 1Disease Models, AnimalHippocampusMembrane MicrodomainsMiceMice, KnockoutNerve DegenerationNeurodegenerative DiseasesNeuronsSignal TransductionSynapsesSynaptosomesCaveolin 1

Identifiers

PMID21203469
PMCPMC3009734
OpenAlexW2016486782

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.